MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) reported the filing and acceptance by the U.S. Food and Drug Administration (FDA) of BDSI’s first Investigational New Drug Application (IND) for the company’s Bioral® cochleate drug delivery technology.
